Introduction Idiopathic pulmonary fibrosis (IPF) is one of the most common subtypes of chronic progressive fibrosing lung disease, with an estimated global incidence between 0.9 and 13 per 100 000 persons [1]. Whilst patients with IPF typically have declining lung function with poor prognosis following diagnosis, their disease trajectories vary [2]. Current gold standard therapy for IPF includes antifibrotic drugs, which significantly slow disease progression and confer survival benefits [3].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile